

해외 바이오의약품 임상 현황 ('23년 7월 4주)

한국바이오의약품협회, 2023.08.01.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2023.07.24.~2023.07.30.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05932654	POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis	Drug: BSI-045B Drug: Dupilumab	Biosion, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05932654&rank=1
NCT05903794	A Study of EXG102-031 in Patients With wAMD (Everest)	Biological: EXG102-031	Exegensis Bio	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05903794&rank=1
NCT05903092	MONalizumab in Combination With durvalumab (MEDI4736) Plus Platinum-based chemotherapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer	Drug: Durvalumab Drug: Monalizumab Drug: Carboplatin or Cisplatin Drug: Etoposide	Hirva Mamdani AstraZeneca Barbara Ann Karmanos Cancer Institute Hoosier Cancer Research Network	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05903092&rank=1
NCT05879120	Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma	Drug: Pembrolizumab Device: Exablate MRgFUS + neoadjuvant pembrolizumab	M.D. Anderson Cancer Center InSightec Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05879120&rank=1
NCT05805371	PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer	Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Scan Procedure: Computed Tomography Radiation: External Beam Radiation Therapy Procedure: Leukapheresis Procedure: Lymphodepletion Therapy	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05805371&rank=1
NCT05568550	Pembro With Radiation With or Without Olaparib	Biological: Pembrolizumab Drug: Olaparib Drug: Androgen Deprivation Therapy Radiation: Radiation Therapy	Zin W Myint Merck Sharp & Dohme LLC University of Kentucky	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05568550&rank=1
NCT05911321	Isa-Pom-Dex in Elderly/Frail Subjects With RRMM	Drug: Isatuximab Drug: Pomalidomide Drug: Dexamethasone	UNC Lineberger Comprehensive Cancer Center Genzyme, a Sanofi Company	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05911321&rank=1
NCT05873205	Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation	Biological: Isatuximab	Memorial Sloan Kettering Cancer Center Sanofi	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05873205&rank=1
NCT05771480	Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)	Biological: Durvalumab Drug: Gemcitabine monotherapy Drug: Gemcitabine + cisplatin Drug: Gemcitabine + oxaliplatin Drug: Gemcitabine + carboplatin Drug: Gemcitabine + cisplatin + S-1 Drug: Gemcitabine + S-1 Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05771480&rank=1

해외 바이오의약품 임상 현황 ('23년 7월 4주)

한국바이오의약품협회, 2023.08.01.

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05936359

○ 프랑스 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05941845	Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy	Drug: Peginterferon Alfa-2A 180 MCG/ML Injectable Solution	Centre Hospitalier Universitaire de Nice	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05941845
NCT05771480	Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)	Biological: Durvalumab Drug: Gemcitabine monotherapy Drug: Gemcitabine + cisplatin Drug: Gemcitabine + oxaliplatin Drug: Gemcitabine + carboplatin Drug: Gemcitabine + cisplatin + S-1 Drug: Gemcitabine + S-1 Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05771480
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05936359

○ 독일 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05771480	Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)	Biological: Durvalumab Drug: Gemcitabine monotherapy Drug: Gemcitabine + cisplatin Drug: Gemcitabine + oxaliplatin Drug: Gemcitabine + carboplatin Drug: Gemcitabine + cisplatin + S-1 Drug: Gemcitabine + S-1 Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05771480
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05936359

○ 중국 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05906524	KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors	Drug: KD6001 Drug: Tislelizumab Drug: Bevacizumab	Shanghai Kanda Biotechnology Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05906524
NCT05940428	A Study of ASKG712 in Patients With Diabetic Macular Edema	Biological: ASKG712	AskGene Pharma, Inc. Suzhou Aosaikang Biopharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05940428
NCT05867030	Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma	Drug: lenalidomide Drug: rituximab Drug: parsaclisib	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05867030
NCT05046314	A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma	Biological: TK216+Vincristin	Shanghai Pharmaceuticals Holding Co., Ltd	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05046314

해외 바이오의약품 임상 현황 ('23년 7월 4주)

한국바이오의약품협회, 2023.08.01.

○ 일본 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05926583	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa	Genetic: AAV5-hRKp.RPGR	Janssen Pharmaceutical K.K.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05926583
NCT05771480	Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)	Biological: Durvalumab Drug: Gemcitabine monotherapy Drug: Gemcitabine + cisplatin Drug: Gemcitabine + oxaliplatin Drug: Gemcitabine + carboplatin Drug: Gemcitabine + cisplatin + S-1 Drug: Gemcitabine + S-1 Drug: Gemcitabine + cisplatin + albumin-bound paclitaxel	AstraZeneca	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05771480
NCT05936359	A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms	Drug: INCA033989 Drug: Ruxolitinib	Incyte Corporation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05936359